Spending investment dollars on compliance can limit R&D and delay R&D so changes like the on-ramp, Congressman Fitzpatrick's legislation, and Congressman Hurt's audit firm rotation bill are important for growing biotechs without product revenue.
Emphasizing the importance of legislative changes for biotech R&D funding.
Share & report
More from Michael Fitzpatrick
The more you can sanction those individuals as government leaders and others who are involved in the corrupt practices and in the financial skullduggery that goes on in the general criminal world, then the less--obviously, the less…
the national debt is a good story, it is a good story to tell about the national debt, and, number two, it is not a threat to our economy.
Other voices in this conversation
